NPR: rheumatoid arthritis https://www.npr.org/templates/story/story.php?storyId=164632370 rheumatoid arthritis en Copyright 2024 NPR - For Personal Use Only Story API Shim 1.2.24 Wed, 09 Apr 2025 05:20:21 -0400 https://media.npr.org/images/podcasts/primary/npr_generic_image_300.jpg?s=200 NPR: rheumatoid arthritis https://www.npr.org/tags/164632370/rheumatoid-arthritis Vagus nerve stimulation may tame autoimmune diseases The next big advance in treating diseases like rheumatoid arthritis could be tiny pulses of electricity delivered to the vagus nerve. Mon, 03 Feb 2025 05:00:47 -0500 https://www.npr.org/sections/shots-health-news/2025/02/03/nx-s1-5272748/vagus-nerve-stimulation-may-tame-autoimmune-diseases https://www.npr.org/sections/shots-health-news/2025/02/03/nx-s1-5272748/vagus-nerve-stimulation-may-tame-autoimmune-diseases

The next big advance in treating diseases like rheumatoid arthritis could be tiny pulses of electricity delivered to the vagus nerve.

(Image credit: Sebastian Kaulitzki/Science Photo Library RF)

]]> Jon Hamilton A new test could save arthritis patients time, money and pain. But will it be used? Stories of chronic pain, drug-hopping, and insurance meddling are all too common among patients with rheumatoid arthritis. Precision medicine offers new hope. Wed, 20 Dec 2023 07:01:50 -0500 https://www.npr.org/sections/health-shots/2023/12/20/1220426603/rheumatoid-arthritis-precision-medicine-humira https://www.npr.org/sections/health-shots/2023/12/20/1220426603/rheumatoid-arthritis-precision-medicine-humira

Stories of chronic pain, drug-hopping, and insurance meddling are all too common among patients with rheumatoid arthritis. Precision medicine offers new hope.

(Image credit: Adam Gault/SPL)

]]> Arthur Allen Blockbuster drug Humira finally faces lower-cost rivals After years of being the world's best-selling drug, Humira faces competition from copycat versions known as biosimilars. One called Yusimry costs a $1,000 or less. Thu, 20 Jul 2023 09:57:28 -0400 https://www.npr.org/sections/health-shots/2023/07/20/1188745297/humira-threatened-by-yusimry-low-cost-rival https://www.npr.org/sections/health-shots/2023/07/20/1188745297/humira-threatened-by-yusimry-low-cost-rival After years of being the world's best-selling drug, Humira faces competition from copycat versions known as biosimilars. One called Yusimry costs a $1,000 or less.

]]> Sydney Lupkin Why Hoarding Of Hydroxychloroquine Needs To Stop Despite Trump's public remarks, infectious disease experts say it's premature to think hydroxychloroquine will help against COVID-19. And patients with lupus or rheumatoid arthritis rely on the drug. Mon, 23 Mar 2020 16:28:00 -0400 https://www.npr.org/sections/health-shots/2020/03/23/820228658/why-hoarding-of-hydroxychloroquine-needs-to-stop https://www.npr.org/sections/health-shots/2020/03/23/820228658/why-hoarding-of-hydroxychloroquine-needs-to-stop

Despite Trump's public remarks, infectious disease experts say it's premature to think hydroxychloroquine will help against COVID-19. And patients with lupus or rheumatoid arthritis rely on the drug.

]]> Martha Bebinger FDA-Approved Knock-Offs Of Biotech Drugs Could Safely Save Big Bucks Drugs that consist of proteins and antibodies typically made by living organisms represent the new frontier in drug industry competition. Mon, 01 Aug 2016 17:01:29 -0400 https://www.npr.org/sections/health-shots/2016/08/01/488255920/fda-approved-knock-offs-of-biotech-drugs-could-safely-save-big-bucks https://www.npr.org/sections/health-shots/2016/08/01/488255920/fda-approved-knock-offs-of-biotech-drugs-could-safely-save-big-bucks

Drugs that consist of proteins and antibodies typically made by living organisms represent the new frontier in drug industry competition.

(Image credit: Sebastien Bozon)

]]> Alison Kodjak New Pill For Rheumatoid Arthritis Gets FDA Nod Xeljanz, a new rheumatoid arthritis drug, is the first one that works by blocking enzymes called janus kinases. They play a communication role inside the body and are involved in inflammation associated with rheumatoid arthritis. Wed, 07 Nov 2012 16:54:00 -0500 https://www.npr.org/sections/health-shots/2012/11/07/164617712/new-pill-for-rheumatoid-arthritis-gets-fda-nod https://www.npr.org/sections/health-shots/2012/11/07/164617712/new-pill-for-rheumatoid-arthritis-gets-fda-nod

Xeljanz, a new rheumatoid arthritis drug, is the first one that works by blocking enzymes called janus kinases. They play a communication role inside the body and are involved in inflammation associated with rheumatoid arthritis.

]]> Scott Hensley